Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC_50/90, 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC_50/90, ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC_50/90, 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at ≤8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of S. maltophilia infections, addressing a major unmet medical need.

中文翻译：

---

当对照来自世界各地医疗中心的大量当代嗜麦芽单胞菌麦芽糖分离物进行测试时，氨曲南-阿维巴坦和比较剂的抗菌活性。

测试了Aztreonam-avibactam对全球范围内收集的1,839个嗜麦芽窄食单胞菌的分离物，并显示出对来自所有地理区域和感染类型的分离物的有效活性（总体MIC ₅₀ / _90，4 /4 mg / l; 98.8％≤8mg / l被抑制）。甲氧苄氨磺胺甲基异恶唑（TMP-SMX）（MIC ₅₀ / ₉₀，≤0.5/ 1 mg / L；易感性95.4％）和米诺环素（MIC 50 / _90，0.5 / 2 mg / L；易感性99.5％）也非常活跃。Aztreonam-avibactam抑制≤8 mg / L的非TMP-SMX敏感分离株的84.7％。Aztreonam-avibactam可能代表治疗嗜麦芽孢杆菌感染的有价值的选择，可解决尚未满足的主要医疗需求。